News
Success with pre-Clinical Milestone triggers Payment
Oct 15 2021
Clinical stage biopharmaceutical Avacta Group has announced achievement of a pre-clinical milestone in its multi-target therapeutics development partnership (ILM No, 2020) with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, resulting in an undisclosed milestone payment.
The agreement allows LG Chem development rights on a world-wide basis of Avacta’s Affimer® PD-L1 inhibitor with Affimer XT® serum half-life extension, along with some other biotherapeutics combined with Affimer XT® half-life extension for a range of indications.
LG Chem has successfully completed certain pre-clinical in-vivo models in the PD-L1/XT programme leading to the selection of a pre-clinical candidate for further development towards the clinic which triggered the payment.
Dr. Alastair Smith, Chief Executive of Avacta Group, commented: “I am delighted with the progress in our important strategic partnership with LG Chem. LG Chem is a world-class drug development partner with excellent biologics manufacturing and clinical development capabilities and a pioneering vision to develop innovative drugs.
“I am particularly pleased that we have achieved this significant milestone with a novel Affimer® bispecific product, which highlights the tremendous promise of the Affimer® platform.”
More information online
Digital Edition
ILM Guide 2025/26
June 2025
Buyers' Guide Listings- Product Listings by Category- Suppliers Listings (A-Z)Chromatography Articles- Setting the power coefficient and the baseline to linearise the signal of the evaporative ligh...
View all digital editions
Events
Jun 24 2025 Warsaw, Poland
Jun 24 2025 Shanghai, China
Discovery & Development Europe 2025
Jul 01 2025 Basel, Switzerland
Jul 01 2025 Manchester, UK
Jul 08 2025 Johannesburg, South Africa